Altamira Therapeutics Ltd - Warrants (29/03/2028)
CYTOW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.13M
Close$
Share Statistics
| Market cap | $1.13 Million |
|---|---|
| Enterprise Value | $495,985.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -241.19% |
|---|---|
| Return on Assets | -183.01% |
| Return on Invested Capital | -34.88% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.4 |
| Enterprise Value to EBIT | -0.19 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.73 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Altamira Therapeutics Ltd
17 employees
CEO: Thomas Meyer Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal be...